The purpose of this study
was to analyze the effects of the treatment with Exenatide joint to insulin
detemir. The study was carried out with obese patients with type 2 diabetes
mellitus (DM2) and deficient control, despite intensive insulin therapy
combined with oral antidiabetics. A longitudinal study was made with 15
patients controlled by the Endocrinology and Nutrition Section of the Reina
Sofía University Hospital, Murcia. These patients were treated with Exenatide joint
to insulin during 3, 6 and 12 months. Statistically meaningful differences (p
< 0.05) were observed in the reduction of HbA1c in the 3 and 6 months
treatment groups (initial HbA1c: 9.55% ± 1.086%, weight: 119.94 kg, insulin
requirement: 0.71 IU/kg/day; after 3 months: HbA1c: 7.77% ± 1.164%, weight:
98.13 kg, insulin requirement: 0.59 IU/kg/day; after 6 months: HbA1c: 7.21%,
weight: 97.93 kg, insulin requirement: 0.55 IU/kg/day). It was observed that
the association of Exenatide and insulin promotes an improvement in several
indicators such as weight, body mass index (BMI), systolic pressure (SP),
diastolic pressure (DP), triglycerides (TG), cLDL, cHDL and total cholesterol
(TC), in patients with diabetes resistant to conventional therapy. However,
these improvements were statistically no significant (p < 0.05). It is
possible to talk of a reduction of cardiovascular risk factors in patients with
Exenatide, being thus a suitable option for this kind of individuals. It is
important to emphasize the fact that our study showed bigger body-weight
reductions results after 6 and 12 months, as compared to the researches quoted.